| 95% CrI | Probability that Treatment Shows Clinical Improvement Over Placebo (≥ 10 mm VAS) | |||
|---|---|---|---|---|
| Comparator (mg) | Difference in CFB* | Low | High | |
| nsNSAIDs | ||||
| naproxen 1000 | -12.9 | -17.7 | -8.2 | 0.89 |
| ibuprofen 2400 | -9.0 | -13.1 | -5.0 | 0.31 |
| diclofenac 150 | -16.2 | -20.6 | -11.7 | >0.99 |
| COX-2 selective NSAIDs | ||||
| celecoxib 200 | -14.7 | -17.3 | -12.1 | >0.99 |
| lumiracoxib 100 | -11.9 | -19.6 | -4.3 | 0.68 |
| lumiracoxib 200 | -11.8 | -19.6 | -4.2 | 0.66 |
| lumiracoxib 400 | -13.9 | -21.5 | -6.1 | 0.85 |
| etoricoxib 30 | -14.2 | -16.8 | -11.6 | >0.99 |
| etoricoxib 60 | -16.2 | -19.8 | -12.7 | >0.99 |